Evaluating the recombinant T24H enzyme-linked immunoelectrotransfer blot assay for the diagnosis of neurocysticercosis in a panel of samples from a large community-based randomized control trial in 60 villages in Burkina Faso by Dermauw, Veronique et al.
Am. J. Trop. Med. Hyg., 98(2), 2018, pp. 565–569
doi:10.4269/ajtmh.17-0541
Copyright © 2018 by The American Society of Tropical Medicine and Hygiene
Evaluating the Recombinant T24H Enzyme-Linked Immunoelectrotransfer Blot Assay for the
Diagnosis of Neurocysticercosis in a Panel of Samples from a Large Community-Based
Randomized Control Trial in 60 Villages in Burkina Faso
Veronique Dermauw,1* He´le`ne Carabin,2 Assana Cisse´,3 Athanase Millogo,4 Ze´kiba Tarnagda,3 Rasmane´ Ganaba,5 John Noh,6
Sukwan Handali,6 Kathleen Breen,6 Vivian Richter,7 Rabiou Cisse´,8 Pierre-Marie Preux,9 Marie-Paule Boncoeur-Martel,10
Andrea Sylvia Winkler,11,12 Anke Van Hul,1 Pierre Dorny,1,13 and Sarah Gabrie¨l14
1Department of Biomedical Sciences, Institute of TropicalMedicine, Antwerp, Belgium; 2Department of Biostatistics andEpidemiology, University
of OklahomaHealth SciencesCenter, OklahomaCity, Oklahoma; 3Institut de Recherche en Sciences de la Sante´ (IRSS), Bobo-Dioulasso, Burkina
Faso; 4Department of Medicine, CHU Souroˆ Sanou, Bobo-Dioulasso, Burkina Faso; 5AFRICSante´, Bobo Dioulasso, Burkina Faso; 6Division of
Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia; 7Department for Diagnostic and Interventional
Radiology, EberhardKarls University Tuebingen, UniversityHospital Tuebingen, Tu¨bingen,Germany; 8Department of Radiodiagnosis andMedical
Imagery, Yalgado Ouedraogo University Hospital Center, Ouagadougou, Burkina Faso; 9Tropical Neuroepidemiology, Institute of Neuro-
epidemiology and Tropical Neurology, INSERM, University of Limoges, CHU Limoges, Limoges, France; 10Hoˆpital Universitaire Dupuytren,
Limoges, France; 11Department of Neurology, Center for Global Health, Technical University Munich, Munich, Germany; 12Department of
Community Medicine andGlobal Health, Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway; 13Department
of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium; 14Department of Veterinary
Public Health and Food Safety, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
Abstract. Current guidelines for the diagnosis of neurocysticercosis (NCC) recommend the use of the lentil lectin-
bound glycoprotein enzyme-linked immunoelectrotransfer blot assay (LLGP-EITB) as the reference standard for sero-
logical testing. In response to thedrawbacks involvedwith the useof the LLGP-EITB, a recombinant T24Hantigen (rT24H)
EITB assaywasdeveloped,with promising results. However, the test has yet to be evaluated among individuals fromsub-
Saharan Africa (SSA). The aim of the present study was to investigate the performance of the rT24H EITB assay for the
detection ofNCCcases in a panel of serumsamples (N=366, ofwhich 173patients presentedwith epileptic seizures and/
or severe chronic headaches, and 193 matched manifestation-free participants) collected as part of a large community-
based trial in Burkina Faso. A perfect agreement between the rT24H EITB and the native gp24 (and its homodimer, gp42)
LLGP-EITB was found (kappa value of 1.0). Furthermore, among patients with the neurological manifestations of interest
who underwent a computed tomography scan, the rT24HEITB andnative antigen LLGP-EITB had a comparable ability to
correctly identify NCC cases with multiple viable (rT24H: sensitivity: 80.0%), single viable (66.7%), and calciﬁed/
degenerating cysts only (25.0%), albeit for multiple viable and calciﬁed cysts, the rT24H estimated sensitivity seemed
lower, butmore uncertain, than previously reported. The rT24HEITB speciﬁcity was high (98.2%) and in linewith previous
studies. This study conﬁrms the valueof the recombinant rT24HEITBasanalternative to the native antigenLLGP-EITB for
the diagnosis of NCC in a SSA community setting.
INTRODUCTION
Invasion of the brain with the larval stage of the tapeworm
Taenia solium causes neurocysticercosis (NCC), a neglected
zoonotic disease targeted for control by the World Health
Organization.1 In endemic areas, the disease is a major cause
of epilepsy, with an estimated 29% of people with epilepsy
being affected.2 Other signs and symptoms of NCC include
progressively worsening severe chronic headache (SCH) and
cognitive decline.3
Currently, experts advise using a combination of neuro-
imaging results, the presence of speciﬁc clinical/neurological
presentations, results from immunodiagnostic tests in serum
or cerebrospinal ﬂuid, and/or epidemiological factors, among
others, to diagnose NCC.4,5 The lentil lectin-bound glyco-
protein enzyme-linked immunoelectrotransfer blot assay
(LLGP-EITB)6 is considered the most accurate immunodiag-
nostic test for NCC diagnosis, with a positive test result being
considered a major diagnostic criterion.4 The LLGP-EITB
detects antibodies against glycoproteins found in the soluble
fraction of an extract of T. solium cysticerci7 and has an ex-
cellent test performance with a reported sensitivity of 94%
and speciﬁcity of 100% for multiple enhancing intracranial
lesions.8 The LLGP-EITB assay is, however, expensive and
impractical, especially for application in low resource and
community-based settings because of its need for collection
of cysts from naturally infected pigs and extensive expertise
with the assay technique.9
To overcome these drawbacks, the Centers of Disease
Control and Prevention of the United States (CDC) developed
and evaluated an EITB assay based on the representative
recombinant or synthetic forms of antigens (Ag) from each of
the three distinct antigenic protein families of the LLGP-EITB
assay: gp50, gp24, and 8-kDa.7 In an evaluation study mainly
analyzing serum panels of NCC patients from Peru, the EITB
assay based solely on the recombinant T24H (rT24H) Ag,
belonging to the gp24 antigenic protein family, was 99%
sensitive and 100% speciﬁc in detecting NCC cases with
more thanoneviable cyst.7 Theagreement between the rT24H
EITB and the full native antigen EITB assay (LLGP-EITB) was
almost perfect (kappa value = 0.89).7 Based on this agree-
ment, and excellent performance of the rT24H in the same and
earlier studies using the rT24H in amultiple assay format,10–12
the authors concluded that the recombinant T24H in a single
Ag assay could be a valuable alternative for the native com-
bination Ag LLGP-EITB.7
We are not aware of any other study having compared the
performance of the rT24H in a single assay format and the
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native Ag EITB assay for NCC diagnosis. Furthermore, no
published study has evaluated the performance of rT24HEITB
assay as a serological test for NCC diagnosis in individuals
from sub-Saharan Africa (SSA). Therefore, the aims of this
study were to 1) investigate the agreement between the rT24H
EITB assay versus theCDCLLGP-EITB and a commercialized
EITBand2) evaluate theperformanceof the rT24HEITB for the
detection of NCC in people with single or recurrent seizures
and SCH, in a panel of serum samples collected in a large
scale community-based randomizedcontrolled trial inBurkina
Faso.
MATERIALS AND METHODS
Study design and participants. The sera originated from a
subgroup of participants in the baseline cross-sectional
component of a large community-based randomized con-
trolled trial (E´valuation du Fardeau E´conomique de la Cys-
ticercose au Burkina [EFECAB]), conducted in 60 villages in
Burkina Faso.13 Each consenting participant was asked to
answer a screening questionnaire including questions about
thepresenceof epileptic seizures andSCH (seeSupplemental
material).
An epileptic seizure was deﬁned as an unprovoked seizure
without an apparent cause. Participants with either recurring
or single epileptic seizures were included. SCHs were deﬁned
as symptoms arising more than weekly for more than 2 weeks
with each episode lasting at least 3 hours, and progressively
worsening in severity with time. Headaches had to be severe
enough to require painkillers or to prohibit working, playing,
attending school, or partaking in daily activities.14
Sera of all participants who were, based on the individual
screening questionnaire and a medical examination by a
physician of those screened positive, classiﬁed as having
single or recurrent epileptic seizures, or SCH, referred to as
“patients with neurological manifestations,” were included in
the test panel. In addition, sera from randomly selected indi-
viduals who declared no symptoms on the questionnaire and
were not examined by a physician, frequencymatched by age
groups, gender, and village to the cases, were included, re-
ferred to as “manifestation-free participants.”
Samples and analytical procedures. A total of 199 and
199 serum samples of participants initially classiﬁed by the
study physician as patients with neurological manifestations
of interest or manifestation-free participants, respectively,
were selected (Figure 1). Of these, enough sera remained to
analyze 182 and 184 samples of participants with and without
neurological manifestations, respectively. Following further
examination of patient ﬁles by the neurologist, nine individuals
initially being classiﬁed as patients with neurological mani-
festations were reclassiﬁed as being manifestation-free par-
ticipants, leaving sera of 173 patients with neurological
manifestations and 193 manifestation-free participants avail-
able for the analysis (N = 366). This panel of sera was sub-
jected to analysis with the LLGP-EITB run at the CDC as well
as the rT24H and rGP50 EITB assays, using procedures de-
scribed earlier.6,7 For the LLGP-EITB, results for reactions to
any of the antigenic protein families, gp24 (including reactions
to its homodimer gp42), gp 50, and 8-kDa, were presented.
The sampleswere also subjected to a commercial LLGP-EITB
assay, the Qualicode™ Cysticercosis EITB Kit, following
manufacturer’s instructions (Immunetics Inc, Boston,MA), yet
because of a prolonged interruption in diagnostic kit delivery
by the distributor, only 223 samples (103 patients with neu-
rological manifestations, 120 manifestation-free participants)
could eventually be analyzed.
Neuroimaging. Brain imaging results obtained by en-
hanced computed tomography (CT) scans both with and
FIGURE 1. Sampling scheme. The participants’ responses to the screening questionnaire were reviewed by the study physician and reexamined
by the neurologist thereafter. Participants were classiﬁed as being “patients with neurological manifestations” or “manifestation-free participants.”
The commercial enzyme-linked immunoelectrotransfer blot (EITB) test panel was smaller than the other serum test panels because of the shortage
of diagnostic kits from the distributor. See also MATERIALS AND METHODS.
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without contrast were available for 151 of 173 patients with
neurological manifestations; the remaining 22 individuals re-
fused to undergo a CT scan. The presence of NCC lesions on
CT scans and their classiﬁcation was evaluated by three ra-
diologists; scans for which there was a disagreement were
additionally evaluated by a neurologist. CNS lesions were
classiﬁed as “uncertain” in situations where no agreement
could be reached among the radiologists and the neurologist,
“calciﬁed/degenerating cysts” when only calciﬁed or degen-
erating cysts were identiﬁed, and “single viable cysts” or
“multiple viable cysts” when one or more live cysts with or
without scolex were identiﬁed. Patients with single or multiple
viable cysts could also harbor degenerating or calciﬁed cysts,
yet for these patients, only the presence of the viable cysts
was described, and sera were categorized accordingly.
Dataanalysis.The agreement betweenantibody-detecting
tests was assessed on the full panel of serum samples
obtained from patients with neurological manifestations and
matched manifestation-free participants and was expressed
bymeans of the Cohen’s kappa statistic,15 with a kappa value
of 0.01–0.20 indicating “slight” agreement between tests,
whereas kappa values of 0.21–0.40, 0.41–0.60, 0.61–0.80,
and > 0.81 indicate “fair,” “moderate,” “substantial,” and “al-
most perfect” agreement, respectively.16
The performance (sensitivity and speciﬁcity) of evaluated
tests was assessed in the panel of serum samples of the pa-
tients with neurological manifestations who underwent CT
imagingwith conclusive NCCdiagnosis (called “NCCcases”).
In the context of this performance assessment, CT imaging
was considered as the gold standard. Statistical analyses,
including calculation of 95% conﬁdence intervals (95% CI),
were conducted using the binom.test, Kappa test, and con-
fusionMatrix commands in R, version 3.3.1.17
Ethical clearance. Serum samples were collected and
imaging was performed in compliance with protocols ap-
proved by the University of OklahomaHealth SciencesCenter
Institutional Review Board (USA) and by the Center MURAZ
ethical review panel (Burkina Faso). An informed consent was
obtained from adult participants and from parents or legal
guardians of minors. All patients received care according to
the national guidelines.
RESULTS AND DISCUSSION
The present study aimed to evaluate the performance of the
rT24H EITB assay for the detection of NCC cases in a panel of
serum samples collected in a large scale community trial in
Burkina Faso. As such, it is the ﬁrst study evaluating the rT24H
EITB in samples collected in SSA. Our serum panel included
sera of 173 patients with neurological manifestations, identi-
ﬁed in a community setting, of which ﬁve suffered from single
epileptic seizures, 13 from recurrent epileptic seizures and
SCH, 75 from recurrent epileptic seizures only, and 80 from
SCH only, as well as 193 manifestation-free participants. Of
the 366 samples analyzed, 34 were positive to the LLGP-EITB
assay run at the CDC (34/366, 9.3%, 95% CI: 6.5–12.7). Of
these 34 positive samples, 26 showed reactivity to the native
gp24, gp42, and gp50 Ag (26/366, 7.1%, 95% CI: 4.7–10.2),
whereas eight only reacted to the native gp50 Ag (8/366,
2.2%, 95% CI: 0.9–4.3). Furthermore, of the 34 positive
samples, weak reactions to at least one of the native Ag were
observed for nine samples (9/366, 2.5%). Of the 366 samples
analyzed, 26 were found positive on the rT24H EITB assay
(26/366, 7.1%, 95% CI: 4.7–10.2), for which weak reactivity
occurred in four samples (4/366, 1.1%, 95%CI: 0.3–2.8), all of
which had aweak reaction to the native gp24Ag on the LLGP-
EITB. None of the samples showed reactivity to the 8-kDa
antigenic family in the LLGP-EITB (0/366, 0.0%, 95% CI:
0.0–1.0).
Theagreement between the rT24HEITBand theLLGP-EITB
test results was almost perfect (kappa value: 0.85; 95% CI,
0.76–0.95), and non-concordance could be attributed entirely
to reactions to the native gp50Ag. Therefore, the recombinant
Ag EITB format was conﬁrmed to be a valuable alternative for
the LLGP-EITB as suggested in earlier studies.7,10–12 The
agreement between the combined result of the rT24H and
rGP50 versus the LLGP-EITBwasagain almost perfect (kappa
value: 0.90; 95% CI: 0.83–0.98). Non-concordant results for
three of six samples were due to the presence of reaction to
the rGP50, whereas the other three were due to reactivity to
thenative gp50Ag in theLLGP-EITB. It is known that reactions
to the gp50 antigenic family alone can be caused by cross-
reactions with other parasites, and the presence of a non-
speciﬁc “bogus band” near or at the location of the true
50-kDa band may render interpretation difﬁcult.18 Its contin-
ued inclusion in the LLGP-EITB is, however, advised because
sera from some patients alone exhibit reactivity to this band.6
This was also observed in the present study, for two NCC
cases with calciﬁed/degenerating cysts only. The agreement
between the rT24H EITB and the native Ag gp42 and gp24
LLGP-EITB was perfect (kappa value of 1.0) and higher than
the agreement reported earlier.7 A commercial EITB was
performed in 223 of 366 samples, with a positive test result for
35 samples (35/223, 15.7%, 95% CI: 11.2–21.1). The overall
agreement between the commercial EITB and the LLGP-EITB
run at the CDC was substantial (kappa value of 0.69, 95% CI:
0.55–0.84), with a discordant result for 16 serum samples, 13
being positive on the commercial EITB and negative on the
LLGP-EITB, and vice versa for three other. As far as we are
aware, this is the ﬁrst study comparing the performance of
these two tests.
For 28 cases of the 151 patients with neurological mani-
festationswhounderwent imaging, NCCwasdiagnosed upon
imaging (28/151, 18.5%, 95% CI: 12.7–25.7), whereas for 10
cases, the NCC diagnosis was uncertain (10/151, 6.6%, 95%
CI: 3.2–11.8.2); serum samples of the latter group were ex-
cluded from further analysis. Of the NCC cases, 20 had ex-
clusively degenerating or calciﬁed cysts (20/28, 71.4%, 95%
CI: 51.3–86.8), whereas three had a single viable and
ﬁve multiple viable cysts (3/28, 10.7%, 95% CI: 2.3–28.2;
5/28, 17.9%, 95% CI: 6.1–36.9, respectively). Among NCC
cases with viable cysts, seven of eight also had multiple
degenerating/calciﬁed cysts, as mentioned earlier, sera from
these patients were classiﬁed based on the presence of viable
cysts. For 113 individuals, imagingwasnegative forNCC (113/
151, 74.8%, 95% CI: 67.1–81.5).
The ability to correctly identify NCC cases among patients
with neurological manifestations seemed similar for the dif-
ferent antibody-detecting tests (Table 1), although in contrast
to earlier studies,7,10 we did not observe a superior sensitivity
of the rT24H versus the rGP50 EITB assays. Sensitivities for
detecting NCC cases with single and multiple viable cysts
were similar (66.7–100.0%) for most tests and much higher
than for NCC cases with degenerating or calciﬁed cysts only
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(25.0–38.5%) (see Table 1 for 95% CI), the latter being ob-
served in earlier studies as well.7,10,12 Earlier studies also re-
ported higher rT24H EITB sensitivities in NCC cases with
multiple viable cysts versus thosewith a single cyst,7,10,12 yet,
in the present study, sensitivities for detection of these two
classes of patients seemed similar. Numerically, the rT24H
EITB sensitivities seemed lower than those observed in the
earlier work, with reported sensitivities of 94–99% in NCC
cases with multiple viable lesions and 45–73% in those with
calciﬁed/degenerating cysts.7,10,12 By contrast, for caseswith
single viable cysts the rT24H EITB sensitivity were in line
with those reported earlier (44–64%).7,10,12 These estimates
are, however, highly uncertain as suggested by the wide
conﬁdence intervals. The speciﬁcity was excellent and com-
parable for all evaluated antibody detecting tests, except for
the commercial EITB test for which it seemed lower (94.0%
versus 98.2%). The rT24H EITB speciﬁcity estimate was
similar to the 98–100% reported in previous studies.7,10,12
Overall, we must emphasize the small number of NCC cases
in the present study, inevitably causing great uncertainty sur-
rounding the sensitivity values reported, especially for those
cases with viable cysts. Furthermore, our study group is in-
herently different from the ones in previous studies,7,10,12 where
serum samples for determination of sensitivity were all obtained
at a referral hospital in urban Peru, and thus, in a clinical setting
where cases were likely to have more severe symptoms than in
this study. Samples for speciﬁcity determination in that study
wereobtained fromhealthy residents fromtheUnitedStatesand
Egypt, in whom the presence of NCC is highly unlikely.7,10,12 In
our study, sampled individuals were all living in rural communi-
ties in an endemic area in Burkina Faso. Furthermore, sensitivity
and speciﬁcity determinations in the present study were based
on serum samples from patients with neurological manifesta-
tions linked to NCC, all of whomunderwent CT imaging. Finally,
the use of CT imaging as gold standard for the performance
analysis equally has some drawbacks as small calciﬁed cysts
can be missed, so could viable cysts.19,20
Our results conﬁrm that the recombinant T24H EITB is a
valuable, cheaper, and easier to apply alternative to the native
antigen LLGP-EITB, considered the current serological refer-
ence test forNCCdiagnosis. Furthermore, this is theﬁrst study
evaluating the performance of the rT24H EITB assay for NCC
diagnosis in people with single or recurrent seizures and SCH,
in a community-based setting in SSA.
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